Combination Chemotherapy with Nedaplatin and Cyclophosphamide in Human Ovarian Cancer Model

Naomi Uchida, Hiroshi Yoshida, Hajime Yamada, Tohru Wada, Kouji Daikatsu, Isao Ikeuchi, Kenji Sugita and Takayuki Yoshioka

1Shionogi Research Laboratories and 2Chemical Analysis Laboratories, Shionogi & Co., Ltd., 5-12-4 Sagisu, Fukushima-ku, Osaka 553-0002

The antitumor efficacy of the combination of nedaplatin (NDP) with cyclophosphamide (CPM) was evaluated using human ovarian cancer models. Since NDP has been found to have greater antitumor activity and lower nephrotoxicity than cisplatin (CDDP), we also compared the antitumor activity of NDP plus CPM with that of CDDP plus CPM. Increasing doses of NDP (16.5, 33 and 66 mg/kg as a total dose) and a fixed amount of CPM (174 or 348 mg/kg as a total dose) were injected three times at intervals of 7 days via the tail vein into mice implanted with RMUG-S, OC9-JCK or KF-28 human ovarian cancer. Simultaneous administration of NDP with CPM resulted in markedly enhanced inhibition of tumor growth for all cancers tested. The growth inhibition and survival effect of the combination therapy of NDP with CPM against KF-28 and OC9-JCK were as potent as those of CDDP plus CPM. Neither increased hematotoxicity nor a significant difference in maximum concentration, half time or area under the curve of platinum or CPM in plasma between the single and combined treatment was found. These results suggest that the combination of NDP with CPM may be clinically effective.

Key words: Nedaplatin — Cisplatin — Cyclophosphamide — Combination chemotherapy — Ovarian cancer

Nedaplatin (NDP) was selected from a series of platinum analogs because of its pronounced antitumor activity against solid tumors including colon carcinoma, lung carcinoma, melanoma and breast cancer, with lower nephrotoxicity than cisplatin (CDDP), in preclinical studies.1–5 In clinical Phase II studies, NDP showed good efficacy against lung,5–7 head and neck,8 testicular,9 and gynecological8,10 cancers. In previous studies, we have demonstrated that NDP shows synergistic antitumor activity against various cancers in combination with etoposide (ETP) or 5-fluorouracil (5-FU).11,12 Administration of a platinum complex plus an alkylating agent is standard therapy for advanced epithelial ovarian cancer13–16 and the most commonly used combination is CDDP and cyclophosphamide (CPM).17–19 Currently, the combination of CDDP and paclitaxel represents the new standard.20 We have previously demonstrated that NDP showed synergistic antitumor efficacy in combination with CPM against murine and human lung cancer.21 In the present study, we evaluated the augmentation of in vivo antitumor efficacy and toxicity in the combination chemotherapy of NDP plus CPM against three human ovarian cancers, including pharmacokinetic studies. We also compared the therapeutic efficacy of NDP plus CPM with that of CDDP plus CPM.

MATERIALS AND METHODS

Animals BDF1 and athymic BALB/c nude mice (female, 7–9 weeks old) were purchased from Japan SLC Inc. (Shizuoka) and CLEA Japan Inc. (Tokyo), respectively.

Tumors OC9-JCK (human ovarian cancer) was provided by the Central Institute for Experimental Animals (Kawasaki). Human ovarian cancers RMUG-S and KF-28 were kindly provided by Dr. S. Nozawa (Keio University, Tokyo) and Dr. Y. Kikuchi (National Defense Medical College, Saitama), respectively. All tumor cell lines were routinely maintained by serial s.c. transplantation as tumor fragments in BALB/c nude mice. RMUG-S and KF-28 were also maintained in vitro passage using Eagle’s MEM (Nissui Pharmaceutical Co., Tokyo) supplemented with 10% fetal calf serum (Life Technologies Inc., Rockville, MD).

Drugs NDP and CPM were obtained from Shionogi & Co., Ltd. (Osaka). CDDP was purchased from Nippon Kayaku (Tokyo). All drugs were dissolved in saline immediately before use.

In vivo therapeutic experiments The experimental procedure was described previously.11,12 In all experiments, 5 to 10 mice per group were used. On day 0, a tumor fragment (approximately 8 mm³) was implanted s.c. into the back of BALB/c nude mice. Treatment was started when the tumor volume reached approximately 100 mm³. All drugs were administered i.v. once a week for three weeks.
The total doses of drugs used were 16.5, 33 and 66 mg/kg for NDP, 9 mg/kg for CDDP, and 174 or 384 mg/kg for CPM. The maximum tolerated doses (MTDs) of NDP, CDDP and CPM in the route and schedule used in this study were 66, 18 and 348 mg/kg, respectively. The MTDs in combination therapy are either 66 mg/kg of NDP (or 18 mg/kg of CDDP) plus 174 mg/kg of CPM or 33 mg/kg of NDP (or 9 mg/kg of CDDP) plus 348 mg/kg of CPM, because combined treatment with 66 mg/kg of NDP and 348 mg/kg of CPM resulted in toxic death or severe body weight losses. All experiments were performed with the approval of the Shionogi Animal Care and Use Committee.

**Evaluation of antitumor efficacy** Tumor size, body weight and survival were scored throughout each experiment. The endpoint for survival was taken as the time when animals became moribund, exhibiting hypoactivity or hypothermia. The mice were then killed. Relative growth inhibition (RV) was calculated as $RV = V_n / V_0$, where $V_n$: tumor volume on day $n$, and $V_0$: initial tumor volume. The growth-inhibitory effect and prolongation of survival were estimated in terms of the treated/control ratio ($T/C$) and increased life span (ILS%) versus the control, respectively. For the evaluation of combination therapies, the combination index (CI) was used.

The CI was calculated from ILS% values as follows: $CI = \frac{ILS\% \text{ of drug A with drug B}}{ILS\% \text{ of drug A} + ILS\% \text{ of drug B}}$.

A CI of more than 1 indicates synergy, a CI equal to 1 indicates additivity and a CI of less than 1 indicates antagonism.

**Statistics** In this study, the statistical significance of differences between treated and non-treated groups or between treated groups was evaluated using Bonferroni’s test and Dunnett’s test, respectively.

**Hematotoxicity study** NDP (22 mg/kg) and/or CPM (116 mg/kg) were i.v. injected into BDF1 mice and blood samples were collected from the portal vein of anesthe-

---

**Table I. Augmentation of Antitumor Activity in Combination Chemotherapy of Nedaplatin (NDP) with Cyclophosphamide (CPM) against Human Ovarian Cancer**

| Cancer   | Group          | Total dose (mg/kg) | $RV^{(b)}$ (Mean±SD) | $T/C^{(c)}$ | Maximum body weight loss (%)$^{(d)}$ |
|----------|----------------|--------------------|-----------------------|-------------|-------------------------------------|
|          |                | NDP$^{(a)}$        | CPM$^{(a)}$           |             |                                     |
| KF-28    | Untreated control | 0                  | 0                     | 33.4±11.3  | 0.0                                 |
|          | CPM only      | 0                  | 87                    | 14.3±3.2** | 0.43                                |
|          |              | 0                  | 174                   | 4.4±1.9**  | 0.13                                |
|          |              | 0                  | 348                   | 1.9±1.0**  | 0.06                                |
|          | NDP only      | 33                 | 0                     | 17.0±0.6** | 0.51                                |
|          |              | 66                 | 0                     | 4.2±2.1**  | 0.13                                |
|          | Combination  | 33                 | 174                   | 1.1±0.9**  | 0.03                                |
|          |              | 66                 | 174                   | 0.02±0.01**| 0.00                                |
| OC9-JCK  | Untreated control | 0                  | 0                     | 15.2±9.2  | 0.0                                 |
|          | CPM only      | 0                  | 174                   | 3.0±1.5**  | 0.20                                |
|          |              | 0                  | 348                   | 1.7±0.6**  | 0.11                                |
|          | NDP only      | 16.5               | 0                     | 7.9±3.5**  | 0.52                                |
|          |              | 33                 | 0                     | 2.8±1.9**  | 0.18                                |
|          | Combination  | 16.5               | 348                   | 1.1±0.5**  | 0.07                                |
|          |              | 33                 | 348                   | 0.6±0.3**  | 0.04                                |
| RMUG-S   | Untreated control | 0                  | 0                     | 7.8±2.6   | 5.7                                 |
|          | CPM only      | 0                  | 174                   | 7.7±2.4   | 0.99                                |
|          |              | 0                  | 348                   | 4.8±1.5   | 0.62                                |
|          | NDP only      | 16.5               | 0                     | 7.2±2.4   | 0.92                                |
|          |              | 33                 | 0                     | 8.1±2.4   | 1.04                                |
|          | Combination  | 16.5               | 348                   | 4.8±1.3   | 0.62                                |
|          |              | 33                 | 348                   | 3.8±1.2*  | 0.49                                |

$^{(a)}$ i.v. ×3 (days 15, 22, 29 for RMUG-S, days 21, 28, 35 for OC9-JCK, days 12, 19, 26 for KF-28).
$^{(b)}$ Relative tumor volume on day 36 for RMUG-S, on day 42 for OC9-JCK, on day 62 for KF-28.
$^{(c)}$ Treated/control.
$^{(d)}$ % of initial.
\* $P<0.05$, \** $P<0.01$ for no treatment by Bonferroni’s test.
Nedaplatin-based Combination Therapy

**Pharmacokinetic study**  NDP (22 mg/kg) and/or CPM (116 mg/kg) were injected i.v. into BDF1 mice and blood samples were harvested with a heparinized syringe at 5, 30, 60, 120, 240 and 480 min, followed by rapid centrifugation at 600g for 5 min to separate plasma. The platinum content of plasma was determined with a flameless atomic absorption spectrometer (model Hitachi Z-5000, Tokyo). With regard to CPM, the concentration of 4-hydroxycyclophosphamide (4-HCP), an active metabolite of CPM, was determined by means of the fluorometric method as described previously.25)

**In vitro cell culture**  For determination of the in vitro cytotoxic activity of NDP and CPM, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used as described previously.20) KF-28 cells (3000 cells/well) were plated in a 96-well culture plate (Sumitomo Bakelite Co., Tokyo) in 100 µl of culture medium. Twenty-four hours later, serial dilutions of NDP and/or 4-HCP (100 µl) were added to the wells. After a 24 h incubation, the culture medium was removed and the wells were washed three times with Eagle’s MEM followed by additional culture in a CO2 incubator (Tabai Espec Corp., Osaka) for 4 days and cytotoxicity was determined by means of MTT assay. The IC50 values of NDP and CPM for KF-28 cells under the above experimental conditions were 0.9 and 1.1 µM, respectively.

**RESULTS**  Combination therapy of NDP plus CPM against human ovarian cancer  Table I summarizes the results of combination therapy with NDP and CPM against three human ovarian cancers. In all human ovarian cancer models tested, combination therapy of NDP with CPM resulted in enhanced antitumor efficacy. This combination showed greater growth-inhibitory activity than NDP or CPM alone in both KF-28 and OC9-JCK cells. RMUG-S cells, which were rather less sensitive to continuous exposure to NDP in vitro for 4 days (IC50=6.3 µM, data not shown), did not respond to NDP in this experimental therapy. However, tumor growth was significantly (P<0.05) and effectively (T/C<0.5) inhibited at a high dose of NDP in combination with CPM. Although body weight loss during therapy was augmented by the combination of NDP with CPM, it remained within a tolerable range (<20% of the initial body weight) as shown in Table I.

**Combination therapy with NDP plus CPM versus CDDP plus CPM against human ovarian cancer**  Fig. 1
shows the results obtained with NDP plus CPM and CDDP plus CPM (33 mg/kg NDP and 9 mg/kg CDDP) against KF-28 human ovarian cancer. While growth inhibition was enhanced by combined treatment in both cases, the growth-inhibitory activity of NDP plus CPM was superior to that of CDDP plus CPM. A similar but less marked result was obtained with OC9-JCK cells (Fig. 2). Table II shows the effect of both therapies on the survival of OC9-JCK-inoculated mice. The survival time was significantly \((P<0.05)\) increased when mice were treated with NDP and CPM in comparison with either NDP or CPM alone. The combination of CDDP with CPM also resulted in prolonged survival. The mean survival periods of mice treated with NDP plus CPM and CDDP plus CPM were 116±18 and 103±13 days, respectively, indicating comparable survival effects for both treatments. The CI values indicated that the effect was synergistic in the case of NDP plus CPM, but nearly additive in the case of CDDP plus CPM (CI values for NDP plus CPM and CDDP plus CPM were 1.45 and 1.08, respectively). One of six OC9-JCK-bearing mice treated with NDP and CPM survived more than 150 days without recurrence of the tumor.

Table II. Prolonged Survival of OC9-JCK-bearing Mice after Combination Chemotherapy with Nedaplatin (NDP) and Cyclophosphamide (CPM) and Cisplatin (CDDP) with CPM

| Group            | Total dose (mg/kg) | Survival days (individual mice) | MSD \(\pm\) SD | CI \(\pm\) |
|------------------|-------------------|---------------------------------|----------------|---------|
|                  | NDP               | CPM\(\alpha\)                   | MSD \(\pm\) SD | CI \(\pm\) |
| Untreated control| 0                 | 0                               | 68, 58, 66, 70, 61, 58, 62 | 62.1±5.6 |
| CPM only         | 0                 | 174                             | 82, 89, 90, 91, 81, 80 | 85.5±5.1** |
| NDP only         | 33                | 0                               | 75, 79, 80, 77, 85, 58 | 58.7±9.5 |
| Combination      | 33                | 174                             | 116, 110, 107, 110, 110, 100 | >116.2±18.7** | >1.45 |
| CDDP only        | 9                 | 0                               | 72, 68, 72, 82, 75, 84 | 75.5±6.4 |
| Combination      | 9                 | 174                             | 103, 89, 110, 89, 121, 104 | 102.7±12.6** | 1.08 |

\(\alpha\) i.v. \(\times\) 3 (days 21, 28, 35).

** Mean survival days (mean±SD).

\(\alpha\) Combination index.

\(\alpha\) \(P<0.01\) for no treatment by Bonferroni’s test.

Fig. 2. Augmented growth inhibition of OC9-JCK human ovarian cancer by combination chemotherapy with nedaplatin (NDP) plus cyclophosphamide (CPM) (a) and cisplatin (CDDP) plus CPM (b). The experimental protocols are described in “Materials and Methods.” NDP (11 mg/kg), CDDP (3 mg/kg) and CPM (58 mg/kg) were injected i.v. on days 19, 26 and 39. Mice were treated with saline (○), CPM (△), NDP or CDDP (■) or a combination (●). Mean relative tumor volume±SD were shown.
Nedaplatin-based Combination Therapy

Table III. Hematotoxicity of Combined Treatment of NDP with CPM

| Group        | White blood cells (day of nadir) | Red blood cells (day of nadir) | Platelets (day of nadir) | Bone marrow cells (day of nadir) |
|--------------|----------------------------------|--------------------------------|--------------------------|----------------------------------|
| Untreated control | 100±3.5±                  | 100±1.9±                       | 100±3.5±                  | 100±2.0±                        |
| CPM only       | 18±1.0** (3)                | 75±3.3** (3)                   | 86±18.7 (3)              | 23±5.0** (3)                    |
| NDP only       | 59±4.1** (14)               | 86±5.6** (7)                   | 41±2.0** (9)             | 68±1.2** (5)                    |
| Combination    | 18±1.2** (3)                | 74±0.2** (7)                   | 63±6.6** (7)             | 14±2.2** (3)                    |

NDP or CPM was injected i.v. on day 0. Doses of NDP and CPM used were 22 mg/kg and 116 mg/kg, respectively.

a) Percent of untreated control, mean±SD.

b) n=3.

c) Ranges of the mean cell numbers of white blood cells, red blood cells, platelets and bone marrow cells at the various time points were 3.8–5.7×10^3/µl, 7.2–7.9×10^6/µl, 7.6–8.6×10^5/ml and 1.1–1.5×10^7/femur, respectively.

∗, **P<0.05, 0.01 for untreated control by Bonferroni’s test.

Toxicity study The hematotoxicity of NDP with CPM was analyzed (Table III). To minimize the physiological influence of the growing tumor, non-tumor-bearing BDF1 mice were used for this study. NDP (22 mg/kg) and/or CPM (116 mg/kg) were injected i.v. and blood samples were collected 1, 3, 5, 7, 9, 11, 14 and 17 days thereafter. No significant augmentation of hematotoxicity was detected with the combination of NDP and CPM in terms of any parameter. These results demonstrated that combined chemotherapy with NDP and CPM exhibited potent antitumor efficacy against human ovarian cancer without increased toxicity.

In vitro cytotoxicity study In order to clarify the mechanism of the enhancement of antitumor efficacy, in vitro cytotoxicity experiments were done by means of MTT assay using KF-28 cells. One-day exposure to NDP and 4-HCP, an active form of CPM, resulted in additive cytotoxic activity at a low dose (0.2 µM NDP and 0.6 µM CPM), but antagonistic activity at a high dose (0.8 µM NDP and 2.4 µM CPM) (Fig. 3).

Pharmacokinetic study The pharmacokinetics of NDP and CPM were analyzed. No significant difference between the single and the combined treatment was found in terms of the maximum concentration (Cmax), half time (t1/2) and area under the curve (AUC) of platinum or CPM in plasma (Table IV).

DISCUSSION

Extensive preclinical and clinical trials of anticancer agents in various combinations have been conducted in order to increase antitumor efficacy. For advanced ovarian cancer, randomized trials comparing clinical response rates and progression-free survival have established that CDDP-based combination therapy is more effective than single-agent CDDP, single-agent alkylating agents, or combinations without CDDP.13–19, 27, 28

We have previously demonstrated the antitumor efficacy of NDP with CPM against murine and human lung can-
In the present study, we focused on the antitumor efficacy of this therapy against human ovarian cancer. In order to examine effective responses against human ovarian cancers used in this study, which are slow-growing in nude mice, NDP and CPM were administered 3 times with 7-day intervals. Our preliminary data demonstrated that the repeated administration of NDP and CPM was more effective than single treatment (data not shown). Enhancement of growth inhibition (Table I, Fig. 1 and Fig. 2) in NDP plus CPM therapy was demonstrated against three human ovarian cancers tested, including the NDP-sensitive tumor KF-28 and the insensitive tumor RMUG-S. In the OC9-JCK tumor, prolonged survival was also afforded by the combination of NDP with CPM (Table II). The antitumor efficacy of NDP with CPM was superior to the maximum response to either NDP or CPM monotherapy.

We also compared the antitumor activity of NDP plus CPM with that of CDDP plus CPM against KF-28 and OC9-JCK tumors. In the KF-28 model, it was clear that NDP plus CPM was superior to CDDP plus CPM in terms of tumor growth inhibition. Although similar results were also obtained with the OC9-JCK tumor, the T/C values on day 54 in NDP plus CPM and CDDP plus CPM were 0.56±0.68 and 3.00±2.14, respectively, and the difference was not statistically significant (Fig. 2). However, regression of the tumors was found in five of six mice treated with NDP plus CPM even 15 days after the last treatment, but in only one of six mice given CDDP plus CPM therapy. In the experiment using KF-28 cells, tumor regression was also observed in six of six mice given NDP with CPM and in two of six mice given CDDP with CPM (Fig. 1). These results indicated that the combination of NDP with CPM is more effective than that of CDDP with CPM in terms of response rate. It is also noteworthy that three of five KF-28-bearing mice (Fig. 1, data not shown) and one of six OC9-JCK-bearing mice (Table III) treated with NDP and CPM survived more than 150 days without tumor recurrence. No mouse treated with CDDP plus CPM was found to be cured. These results suggest that the combination of NDP plus CPM confers a survival benefit and confirmed our previous finding with murine Lewis lung carcinoma.

Toxicity, in addition to efficacy, must be considered in combination chemotherapy. We therefore first compared the profile of body weight changes among the therapies. As shown in Table I, the maximum body weight losses in animals given NDP plus CPM therapy were within the tolerable range (<20% of the initial body weight) on the administration schedule used in this study. We therefore evaluated the hematotoxicity in the combination therapy at 22 mg/kg of NDP and 116 mg/kg of CPM as a single injection. The numbers of white blood cells, red blood cells and bone marrow cells were mainly decreased by CPM treatment and the number of platelets was mainly decreased by NDP treatment. However, hematotoxicity was not augmented by the combination of the two agents. Thrombocytopenia, a dose-limiting factor of NDP, was not enhanced by the combination with CPM. This should be beneficial for the combination chemotherapy of NDP with CPM, and awaits confirmation in clinical trials.

CDDP/NDP and CPM damage DNA by two different mechanisms; the involvements of DNA strand “kinking” and DNA strand “cross-linking” may explain the positive cell killing interaction between these two drugs. Thus, we first performed in vitro cytotoxicity experiments with CDDP/NDP and/or CPM against three cell lines using MTT assay in order to investigate the mechanism of the interaction of NDP and CPM found in the in vivo study. Simple in vitro exposure to NDP and CPM for 1 day showed additive cytotoxic activity at a low dose but antagonistic activity at a high dose (Fig. 3). A similar result was obtained in the 4-day exposure experiment in which the total AUCs of NDP and CPM were greater than those used in in vivo therapeutic experiments (data not shown). These results suggest that the cell killing interaction may not be sufficient to explain the enhanced in vivo antitumor efficacy of the combination therapy.

We next examined the pharmacokinetics of NDP and CPM administered alone or in combination. The pharmacokinetic parameters, such as $C_{\text{max}}$, $t_{1/2}$, and $AUC$ of NDP or CPM were not affected by the simultaneous adminis-

### Table IV. Pharmacokinetics of NDP and CPM

| Group          | Platinum | CPM |
|---------------|----------|-----|
|               | $C_{\text{max}}$ | $t_{1/2}$ | AUC$_{0-24}^a$ | $C_{\text{max}}$ | $t_{1/2}$ | AUC$_{0-24}^a$ |
| NDP only      | ND       | ND   | ND             | 165.9          | 0.47   | 130.7           |
| CPM only      | 170.2    | 0.17 | 59.6           | ND             | ND     | ND              |
| Combination   | 166.8    | 0.18 | 59.8           | 133.1          | 0.50   | 115.3           |

NDP (22 mg/kg) and/or CPM (116 mg/kg) were i.v. injected.

$a$) $\mu$M.

$b$) Hour.

$c$) $\mu$M$\times$h.

ND: not done.
oration. This finding was supported by the results of an earlier clinical pharmacokinetic study.\(^9\) The enhanced antitumor activity, therefore, may not be due to the altered pharmacokinetics of NDP or CPM, although other possibilities, for example higher intra-tumor drug concentration or delayed clearance from tumor tissue upon simultaneous administration of the two drugs, remain to be checked. A precise understanding of the mechanism of the interaction of NDP and CPM is important for appropriate clinical use of these drugs.

In conclusion, the results presented in this study suggest the potential efficacy of a combination of NDP with CPM for clinical therapy.

ACKNOWLEDGMENTS

We thank Toshiyuki Sakaeda and Kohji Takara for reviewing the clinical pharmacology study in combination chemotherapy. (Received April 1, 1999/Revised May 25, 1999/Accepted June 1, 1999)

REFERENCES

1) Totani, T., Aono, K., Komura, M. and Adachi, Y. Synthesis of (glycolato-O,O′)diammineplatinum (II) and its related complexes. Chem. Lett., 3, 429–432 (1986).
2) Suzumura, S., Kato, T., Ueda, R. and Ohta, K. Effect of treatment schedule on antitumor activity of glycolato-O,O′-diammineplatinum (II), a new platinum derivative: comparison with cis-diaminedichloroplatinum (II). Anticancer Res., 9, 1083–1088 (1989).
3) Shiratori, O., Kasai, H., Uchida, N., Takeda, Y., Totani, T. and Sato, K. Anti-tumor activity of 254-S, a platinum complex, in rodents. In "Recent Advances in Chemotherapy," ed. J. Ishigami, pp. 635–636 (1985). University of Tokyo Press, Tokyo.
4) Koenuma, M., Kasai, H., Uchida, N., Wada, T., Hattori, M., Oguma, T., Totani, T. and Inaba, M. Pharmacokinetic correlation between experimental and clinical effects on human non-small cell lung cancers of cis-diammine glycolatoplatinum (254-S) and cis-diammine dichloroplatinum. Anticancer Res., 15, 417–422 (1995).
5) Kameyama, Y., Okazaki, N., Nakagawa, M., Koshida, H., Nakamura, M. and Gemb, M. Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slices. Toxicol. Lett., 52, 15–24 (1990).
6) Furuse, K., Fukuoka, M., Ohshima, S., Ariyoshi, Y., Fujii, M., Kurita, Y., Hasegawa, K., Homma, T., Tamura, M., Inoue, S., Nishiwaki, Y., Kimura, I. and Niitani, H. Phase II clinical study of (glycolato-O,O′)diammineplatinum (II), a new platinum complex, for primary lung cancer. Proc. Am. Soc. Clin. Oncol., 8, 238 (1989).
7) Fukuda, M., Shinkai, T., Eguchi, K., Sasaki, Y., Tamura, T., Ohe, Y., Kojima, A., Oshita, F., Hara, K. and Saijo, N. Phase II study of (glycolato-O,O′)diammineplatinum (II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother. Pharmacol., 26, 393–396 (1990).
8) Inuyama, Y., Miyake, H., Horiiuchi, M., Hayasaki, K., Komiyama, S. and Ohta, K. An early phase II study of cis-diammine glycolato platinum, 254-S, for head and neck cancers. Jpn. J. Cancer Chemother., 19, 863–869 (1992).
9) Akaza, H., Togashi, M., Nishio, Y., Miki, T., Kotake, T., Matumura, Y., Yoshida, O. and Aso, Y. Phase II study of cis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. Cancer Chemother. Pharmacol., 31, 187–192 (1992).
10) Kato, T., Noda, K., Hirabayashi, K. and Nishimura, H. Phase II study of cis-diammine(glycolato)platinum (254-S), a new platinum complex, for gynecological malignancy. Proc. 16th Int. Congr. Chemother., Anticancer Sect., 823, 1–2 (1989).
11) Uchida, N., Kasai, H., Takeda, Y., Maekawa, R., Sugita, K. and Yoshioka, T. Augmented antitumor activity in combination chemotherapy of Nedaplatin with Etoposide. Anticancer Res., 18, 247–252 (1998).
12) Uchida, N., Takeda, Y., Hojo, K., Maekawa, R., Sugita, K. and Yoshioka, T. Sequence-dependent antitumor efficacy of combination chemotherapy of Nedaplatin, a novel platinum complex, with 5-Fluorouracil on in vivo murine tumor model. Eur. J. Cancer, 34, 1796–1801 (1998).
13) Ozols, R. F. and Young, R. C. Chemotherapy of ovarian cancer. Semin. Oncol., 18, 222–232 (1991).
14) Pronzato, P., Bertelli, G., Vigan, A. and Vaira, F. A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancer. Br. J. Cancer, 73, 1425–1427 (1996).
15) McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L. and Davidson, M. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology group). Semin. Oncol., 5, 40–47 (1996).
16) Bolis, G., Favalli, G., Danese, S., Zanaboni, F., Mangili, G., Scarabelli, C., Tateo, S., Valsecchi, M. G., Scarfone, G., Richiardi, G., Frigerio, L., Melpignano, M., Villa, A. and Parazzini, F. Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide for 5 months after cytoreductive surgery for advanced ovarian cancer. J. Clin. Oncol., 15, 1938–1944 (1997).
17) Gershenson, D. M., Wharton, J. T., Copeland, L. J., Stringer, D. A., Edwards, C. L., Kavanagh, J. J. and Stringer, D. A., Edwards, C. L., Kavanagh, J. J., Davidson, M. 31, 1083–1088 (1989).
and cyclophosphamide in advanced ovarian carcinoma: activity and toxicity of ambulatory regimen. Am. J. Oncol., 13, 199–203 (1990).

19) Tibben, J. G., Schijfl, C. P. T. and Beex, L. V. A. M. Results of cyclophosphamide and cisplatin combination chemotherapy in patients with ovarian carcinoma. Eur. J. Gynaecol. Oncol., 13, 331–339 (1992).

20) McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L. and Davidson, M. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin. Oncol., 5, 40–47 (1996).

21) Uchida, N., Takeda, Y., Kasai, H., Maekawa, R., Sugita, K. and Yoshioka, T. Antitumor efficacy of Nedaplatin, a novel platinum complex, with cyclophosphamide in murine and human tumor model. Anticancer Res., 18, 3375–3379 (1998).

22) Kudoh, K., Kikuchi, Y., Hiramatsu, J., Hirata, J., Yamamoto, K., Kita, T. and Nagata, I. Enhancement of antitumor activity of cisplatin by N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine-HCl in human ovarian cancer cells with intrinsic or acquired resistance to cisplatin. Eur. J. Cancer, 33, 122–128 (1997).

23) Wallenstein, S., Zucker, C. L. and Fleis, J. L. Some statistical methods useful in circulation research. Circ. Res., 47, 1–9 (1980).

24) Dunnett, C. W. New tables for multiple comparisons with a control. Biometrics, 20, 482–491 (1964).

25) Ikeuchi, I. and Amano, T. Fluorometric determination of 4-hydroxyifosfamide in blood and urine. Chem. Pharm. Bull., 33, 2416–2420 (1985).

26) Alley, M. C., Scudiero, D. A., Monks, A., Hersey, M. L., Czerwinski, M. J., Fine, D. L., Abott, B. J., Mayo, J. G., Shoemaker, R. H. and Boyd, M. R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res., 48, 589–601 (1988).

27) Neijet, J. P., ten Boxel Huinink, W. W., van der Burg, M. E. L., van Oosterom, A. T., Vriesendorp, R., Kooyman, C. D., van Lindert, A. C. M., Hamerlynck, J. V. T. H., van Lent, M., van Houwelingen, J. C. and Pinedo, H. M. Randomized trial comparing two combination chemotherapy regimens (HEXA-CAF vs CHAP-5) in advanced ovarian cancer. Lancet, ii, 594–600 (1984).

28) Omura, G. A., Blessing, J. A., Ehrlich, C. E., Miller, A., Yordan, E., Creasman, W. T. and Homesley, H. D. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian cancer. Cancer, 57, 1725–1730 (1986).

29) Reed, E., Kohn, E. C., Sarosy, G., Dabholkar, M., Davis, P., Jacob, J. and Maher, M. Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results. Semin. Oncol., 22, 90–96 (1995).

30) Lartigue-Mattei, C., Chabard, J. L., Touzet, C., Chollet, P., Plagne, R., Petit, J. and Berger, J. A. Pharmacokinetics of cyclophosphamide administered alone or in combination with vindesin or cisplatin in 5 patients with bronchial adenocarcinoma. Biomed. Pharmacother., 42, 555–560 (1988).